Shanghai RAAS Blood Products (002252) Stock Price, Fundamentals & Analysis

What 002252 does

Shanghai RAAS Blood Products (002252) is a Healthcare stock in the Biotechnology industry listed on the Shenzhen Stock Exchange. The company, founded in 1988 and headquartered in Shanghai, China, produces and sells blood products in China and internationally. Its portfolio includes albumin (ALBURAAS), intravenous immunoglobulin (GAMARAAS), coagulation factor VIII (HEMORAAS), prothrombin complex (PROTHORAAS), fibrinogen (FIBRORAAS), fibrin sealant (FIBINGLURAAS), and thrombin (THROMBIRAAS), along with specific immune products such as human tetanus and rabies immunoglobulin and hepatitis B immunoglobulin. The company exports its products. In the broader Chinese healthcare space, it operates alongside peers such as Hangzhou Tigermed Consulting (300347), Huadong Medicine (000963), Yunnan Baiyao Group (000538), and Chongqing Zhifei Biological Products (300122), and is part of the Shenzhen Stock Exchange stocks universe.

Key numbers explained

• Price of 5.02 CNY: the most recent trading price per share.
• Market cap of 33.1 mld. CNY: the total market value of all outstanding shares, reflecting the market’s overall valuation of the company.
• Trailing P/E ratio of 26.4: the price-to-earnings ratio calculated using the last 12 months of earnings; it shows how much investors pay per unit of recent earnings.
• Forward P/E ratio of 13.9: a version of the P/E ratio based on expected future earnings, often used to gauge forward-looking valuation.
• Dividend yield of 1.62%: the dividend yield shows the annual dividend as a percentage of the share price, indicating the cash return relative to the price paid.
• Ex-dividend date of 24 iun. 2026: the date on or after which a buyer is no longer entitled to the upcoming dividend.
• Beta of 0.28: a measure of the stock’s volatility relative to the market; a value below 1 suggests lower sensitivity to market swings.
• 52-week range of 4,18 – 6,97: the lowest and highest prices over the past year, useful for context when evaluating the current 5.02 CNY level.

What to watch

Shanghai RAAS Blood Products (002252) operates in the blood products sector, where regulatory approvals, plasma supply, and public health demand are key factors. The trailing 12-month revenue of 6.61 mld. CNY shows a year-over-year decline of -12.7%, which can affect investor sentiment. Profitability metrics such as profit margin of 18.3%, operating margin of 14.5%, and return on equity of 3.7% provide a sense of how efficiently the company converts sales and equity into earnings. The debt-to-equity ratio of 10.9% indicates a relatively low level of debt compared to equity. Investors often compare such figures with those of peers like Aier Eye Hospital (300015), Shijiazhuang Yiling Pharmaceutical (002603), and Asymchem Laboratories (Tianjin) (002821) to understand relative positioning.